广东嘉应制药股份有限公司独立董事 关于第六届董事会第十四次临时会议相关事项的独立意见 广东嘉应制药股份有限公司（以下简称"公司"）于2023年11月20日召开了 第六届董事会第十四次临时会议，公司独立董事徐驰、郭华平、张富明就相关事 项发表了如下独立意见。 一、关于公司拟聘任会计师事务所的独立意见 经核查了解，广东中翼诚会计师事务所具有中国证监会许可的证券、期货相 关业务的执业资格，具备为上市公司提供审计服务的经验和足够的独立性、专业 胜任能力、投资者保护能力。公司本次选聘会计师事务所理由充分合理，选聘程 序符合相关法律法规的有关规定，并与原审计机构中兴华会计师事务所（特殊普 通合伙）进行了充分的事前沟通，不存在损害公司及股东尤其是中小股东利益的 情形。我们同意公司本次关于聘用承办公司 2023 年审计业务的会计师事务所的 议案，并同意将本议案提交公司股东大会审议。 ...

广东嘉应制药股份有限公司 独立董事工作制度 广东嘉应制药股份有限公司独立董事工作制度 （本修订草案已经过第六届董事会第十四次临时会议审议通过，尚待股东大会审议同意） 第一条 为进一步完善广东嘉应制药股份有限公司（以下简称公司）的法人 治理结构，改善董事会结构，强化对内部董事及经理层的约束和监督机制，保护 中小股东及利益相关者的利益，促进公司的规范运作，参照中国证券监督管理委 员会颁布的《上市公司独立董事管理办法》（以下简称《管理办法》）和《上市 公司治理准则》等相关法律法规和规定，结合《广东嘉应制药股份有限公司公司 章程》（以下简称《公司章程》），公司制定独立董事工作制度。 第二条 独立董事是指不在公司担任除独立董事外的任何其他职务，并与其 所受聘的公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者其 他可能影响其进行独立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证券监督管理委员会规定、证券交易所业务规则和公司章程的规 定，认真履行职责，在董事会中发挥参与 ...

| 序号 | 原章程条款 | 修订后章程条款 | | --- | --- | --- | | | 第一百零八条 公司董事会下设审 | 第一百零八条 公司董事会下设审计委员 | | | 计委员会、战略委员会、提名委员 | 会、战略委员会、提名委员会、薪酬与考 | | | 会、薪酬与考核委员会等相关专门 | 核委员会等相关专门委员会。专门委员会 | | | 委员会。专门委员会对董事会负责， | 对董事会负责，依照本章程和董事会授权 | | | 依照本章程和董事会授权履行职 | 履行职责，重大提案应当提交董事会审议 | | | 责，重大提案应当提交董事会审议 | 决定。专门委员会成员全部由董事组成， | | | 决定。专门委员会成员全部由董事 | 其中审计委员会、提名委员会、薪酬与考 | | | 组成，其中审计委员会、提名委员 | 核委员会中独立董事占多数并担任召集 | | | 会、薪酬与考核委员会中独立董事 | 人，审计委员会的成员应当为不在上市公 | | | 占多数并担任召集人，审计委员会 | 司担任高级管理人员的董事，召集人为会 | | | 的召集人为会计专业人士，战略委 | 计专业人士，战略委员会召集人为公 ...

广东嘉应制药股份有限公司 公 司 章 程 （本修订草案已经过第六届董事会第十四次临时会议审议通过，尚待股东大会审议同意） （二○二三年十一月） | 第一章 | | 总则 3 | | --- | --- | --- | | 第二章 | | 经营宗旨和范围 4 | | 第三章 | 股 | 份 4 | | 第一节 | | 股份发行 4 | | 第二节 | | 股份增减和回购 5 | | 第三节 | | 股份转让 6 | | 第四章 | | 股东和股东大会 7 | | 第一节 | | 股东 7 | | 第二节 | | 股东大会的一般规定 10 | | 第三节 | | 股东大会的召集 12 | | 第四节 | | 股东大会的提案与通知 13 | | 第五节 | | 股东大会的召开 16 | | 第六节 | | 股东大会的表决和决议 19 | | 第五章 | | 董事会 24 | | 第一节 | | 董事 24 | | 第二节 | | 董事会 27 | | 第三节 | | 董事会秘书 34 | | 第六章 | | 高级管理人员 36 | | 第七章 | | 监事会 39 | | 第一节 | | 监事 39 | | 第二节 ...

Financial Performance - The company's revenue for Q3 2023 was ¥119,816,763.45, a decrease of 28.58% compared to the same period last year[5] - Net profit attributable to shareholders was ¥6,657,496.96, down 51.28% year-on-year[5] - The basic earnings per share for Q3 2023 was ¥0.0131, reflecting a decline of 51.28% compared to the previous year[5] - Total operating revenue for Q3 2023 was CNY 377,231,434.03, a decrease of 9.0% compared to CNY 414,613,931.27 in the same period last year[22] - Net profit attributable to shareholders increased to CNY 95,184,667.63 from CNY 70,278,629.32, representing a growth of 35.4%[20] - The net profit for Q3 2023 was CNY 24,906,038.31, an increase of 11.8% compared to CNY 22,259,292.60 in Q3 2022[23] - Operating profit for Q3 2023 reached CNY 29,200,819.52, up from CNY 27,589,228.11 in the same period last year, reflecting a growth of 5.8%[23] - Total comprehensive income for Q3 2023 was CNY 24,906,038.31, an increase of 11.8% from CNY 22,259,292.60 in Q3 2022[24] - Basic and diluted earnings per share for Q3 2023 were both CNY 0.0491, up from CNY 0.0439 in the same quarter last year[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥829,462,181.71, a decrease of 2.03% from the end of the previous year[5] - Cash and cash equivalents as of September 30, 2023, were CNY 105,647,839.35, a decrease of 42.6% from CNY 183,858,033.90 at the beginning of the year[18] - Accounts receivable decreased to CNY 125,814,408.47 from CNY 146,026,800.41, reflecting a decline of 13.8%[18] - Inventory increased to CNY 92,041,479.17, up 12.5% from CNY 82,284,816.35 at the beginning of the year[19] - Total assets as of September 30, 2023, were CNY 829,462,181.71, down from CNY 846,650,977.26 at the beginning of the year[20] - Total liabilities decreased to CNY 77,685,566.09 from CNY 118,232,962.76, a reduction of 34.3%[20] - The company reported a total of 558,915,533.97 in current assets, slightly up from CNY 557,432,509.74 at the beginning of the year[19] - Long-term equity investments decreased to CNY 26,077,460.81 from CNY 29,378,955.16, a decline of 11.0%[19] Cash Flow - Cash flow from operating activities increased significantly by 8,632.57%, amounting to ¥52,262,283.61 year-to-date[13] - The company reported a significant increase in cash received from investment activities, rising by 223.77% year-on-year[13] - Cash flow from operating activities generated CNY 52,262,283.61, compared to CNY 598,475.67 in the previous year, showing a significant decline[26] - The company reported a net cash outflow from investing activities of CNY 130,472,478.16, compared to a net outflow of CNY 1,703,881.69 in the previous year[26] Operating Costs and Expenses - Total operating costs for Q3 2023 were CNY 349,993,013.03, down 9.3% from CNY 386,187,135.30 year-on-year[22] - The company incurred total operating expenses of CNY 413,459,740.91, a decrease from CNY 452,484,497.65 in Q3 2022[26] - Research and development expenses decreased to CNY 6,739,497.43 from CNY 7,089,552.01, indicating a reduction of 4.9%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,945[15] - The company’s equity attributable to shareholders increased by 3.21% to ¥751,776,615.62 compared to the end of the previous year[5] - The company experienced a 258.13% increase in trading financial assets compared to the beginning of the year, totaling ¥129,739,200[10]

关于参加2023广东辖区上市公司投资者网上集体接待日活动的公告 证券代码:002198 证券简称:嘉应制药 公告编号:2023-028 1 广东嘉应制药股份有限公司 关于参加 2023 广东辖区上市公司投资者 网上集体接待日活动的公告 本公司及全体董事会成员保证本公告内容的真实、准确和完整,不存在虚假记 载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流,广东嘉应制药股份有限公司(以下简称"公司") 将参加由广东证监局、广东上市公司协会联合举办的"2023广东辖区上市公司投资者集体 接待日活动",现将相关事项公告如下: 本次投资者网上集体接待日活动将采用网络远程的方式举行,投资者可登录"全景路 演"网站(https://rs.p5w.net)参与本次互动交流,活动时间为 2023 年 9 月 19 日(周 二)15:45-17:00。 届时公司高管将在线就公司 2023 年半年度业绩、公司治理、发展战略、经营状况、 融资计划、股权激励和可持续发展等投资者关心的问题,与投资者进行沟通与交流,欢迎 广大投资者踊跃参与! 特此公告。 广东嘉应制药股份有限公司 董事会 2023年 9 月 13 日 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥257,414,670.58, representing a 4.28% increase compared to ¥246,850,964.98 in the same period last year[20]. - The net profit attributable to shareholders was ¥18,248,541.35, a significant increase of 112.32% from ¥8,594,745.92 in the previous year[20]. - The net cash flow from operating activities reached ¥40,045,729.11, marking a 98.72% increase compared to ¥20,152,198.69 in the same period last year[20]. - Basic earnings per share rose to ¥0.0360, up 113.02% from ¥0.0169 in the previous year[20]. - Total assets at the end of the reporting period were ¥821,986,063.88, a decrease of 2.91% from ¥846,650,977.26 at the end of the previous year[20]. - The company's net assets attributable to shareholders increased by 2.29% to ¥745,119,118.66 from ¥728,418,014.50 at the end of the previous year[20]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which was ¥16,770,902.54, up 90.49% from ¥8,804,116.64 in the previous year[20]. - The weighted average return on net assets improved to 2.48%, up from 0.01% in the previous year[20]. - The company achieved total revenue of ¥257,414,670.58, representing a year-on-year growth of 4.28%[55]. - Net profit for the period was ¥18,248,541.35, showing a significant increase of 112.32% compared to the previous year[55]. - The net cash flow from operating activities reached ¥40,045,729.11, an increase of 98.72% due to higher sales collections[67]. Market and Industry Context - The total expenditure on health in China has been steadily increasing, with the proportion of health expenditure to GDP rising year by year, indicating a favorable macroeconomic environment for the pharmaceutical industry[31]. - By the end of 2022, the number of people covered by basic medical insurance reached 1.3457 billion, maintaining a coverage rate of over 95%, with total income from medical insurance funds increasing by 6.9% year-on-year to CNY 3,069.77 billion[31]. - The national centralized procurement of Chinese medicines has expanded, with a selection rate of 71.6% and an average price reduction of 49.4%, which is expected to save over CNY 4.5 billion annually[36]. - The company is positioned to benefit from the ongoing reforms in the healthcare sector, which aim to improve the accessibility and affordability of medicines for the population[32]. - The aging population in China is increasing, with 60 years and older individuals reaching 264 million, a growth of 42.7% since 2010, creating a higher demand for quality healthcare services[40]. Product and R&D Focus - The company focuses on the research, production, and sales of traditional Chinese medicine (TCM) products, specifically proprietary Chinese medicines, which are derived from herbal ingredients and processed into various forms such as pills and powders[29]. - The company plans to strengthen quality control and increase R&D investment to highlight the clinical and scientific value of its products, aligning with industry policies and market conditions[37]. - The company aims to improve its technological processes to enhance the market value of its products, reflecting a commitment to long-term sustainable development[37]. - The company plans to expand its product line by developing new products such as Shuangliao Houfeng tablets and is actively researching other products to diversify its sales structure[89]. - The company is focusing on the clinical and scientific value of its products to enhance market value and consumer trust[42]. - The company plans to strengthen its research and development efforts in response to the evolving regulatory landscape for traditional Chinese medicine[42]. Challenges and Risks - The management highlighted risks related to industry policy changes, product concentration, price declines, cost control, and new drug development[3]. - The overall price of traditional Chinese medicinal materials has significantly increased in the first half of 2023, putting pressure on the company's net profit due to rising manufacturing costs[41]. - The company faces challenges from centralized procurement policies and rising raw material costs, which may impact future performance[41]. - The company's main products, Shuangliao Houfeng San and Jiekou Qili series, are highly concentrated, which poses a risk to revenue and profitability if market fluctuations occur[89]. - The company emphasizes the importance of adhering to national policies and regulations to mitigate risks associated with industry policy changes[87]. Governance and Shareholder Information - The company conducted one annual general meeting and two board meetings during the reporting period, ensuring compliance with governance standards[96]. - The total number of ordinary shareholders at the end of the reporting period is 26,254[137]. - The largest shareholder, Dongfang Securities, holds 11.27% of the shares, totaling 57,200,000 shares[137]. - The company has no limited sale condition shares, with all shares being freely tradable[132]. - There are no changes in the holdings of directors, supervisors, and senior management during the reporting period[139]. Environmental and Social Responsibility - The company has implemented five key environmental protection initiatives, ensuring that pollutant emissions meet national and local standards, resulting in positive social, environmental, and economic benefits[105].

证券代码：002198 证券简称：嘉应制药 公告编号：2023-027 广东嘉应制药股份有限公司 第六届监事会第六次会议决议公告 第六届监事会第六次会议决议公告 4、会议的召集、召开符合法律、法规及公司章程的规定，表决形成的决议 合法、有效。 二、监事会会议审议情况 会议以投票表决方式通过了以下议案： 1、会议以 3 票同意，0票反对，0票弃权审议通过了《关于公司<2023年半 年度报告>及<2023年半年度报告摘要>的议案》； 经审核，监事会认为董事会编制和审核公司《2023 年半年度报告》全文及 摘要的程序符合法律、法规和中国证监会的规定，报告内容真实、准确、完整地 反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本公司及全体监事会成员保证本公告内容的真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 1、广东嘉应制药股份有限公司（以下简称"公司"）第六届监事会第六次 会议通知已于2023年8月15日分别以专人送达、电子邮件或传真等方式送达公司 全体监事。2023年8月25日，会议如期以现场方式举行。 2、会议应到监事3名，实到监事3名。 3、经全 ...

上市公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：广东嘉应制药股份有限公司 金额单位：人民币元 | | | 占用方与上 | 上市公司核 | | 报告期占用累计发生 | 报告期占用 | 报告期偿还累计发 | | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 市公司的关 | 算的会计科 | 期初占用资金余额 | 金额（不含利息） | 资金的利息 | 生额 | 期末占用资金余额 | 原因 | 占用性质 | | | | 联关系 | 目 | | | （如有） | | | | | | | | | | | | | | | | 非经营性 | | | | | | | | | | | | 占用 | | 现大股东及其附属企业 | | | | | | | | | | 非经营性 | | | | | | | | | | | | 占用 | | 小 计 | —— | —— | —— | —— | —— | —— | —— | —— | —— | —— | ...

（一）关于关联方资金占用情况的专项说明和独立意见 报告期内，公司不存在控股股东及其他关联方非经营性占用公司资金的情况，也 不存在以前年度发生并累计至2023年6月30日的违规关联方占用资金情况。 广东嘉应制药股份有限公司独立董事 对第六届董事会第六次会议相关事项的独立意见 广东嘉应制药股份有限公司（以下简称"公司"）第六届董事会第六次会议于2023 年8月25日以现场结合视频和邮件通讯方式召开，公司独立董事郭华平、徐驰、张富 明就报告期相关事项发表了如下专项说明和独立意见： 关于关联方资金往来和对外担保情况的专项说明和独立意见 按照中国证监会《上市公司监管指引第 8 号——上市公司资金往来、对外担保 的监管要求》的要求，本人作为广东嘉应制药股份有限公司的独立董事，通过对公司 2023年上半年关联方资金占用和对外担保情况进行认真地了解和核查，发表独立意见 如下： 2、截至2023年6月30日，公司不存在为控股股东及本公司持股50％以下的其他关 联方、任何非法人单位或个人提供担保的情形，也不存在违规对外担保情况。 3、公司制定了《对外担保管理制度》，规定了对外担保的审批权限、决策程序 和有关的风险控制措施，并严格 ...